BioCardia advances CardiAMP Cell Therapy to formal PMDA consultation for HFrEF in Japan

BioCardia, Inc.

Completed third preliminary clinical consultation with Japan's PMDA for CardiAMP Cell Therapy (HFrEF).
PMDA will allow BioCardia to proceed to formal clinical consultation; potential path to regulatory filing.
Data from three completed Phase I-III trials show improved survival, reduced MACE, and better heart function vs control.
CEO Peter Altman notes therapy offers a new mechanism of microvascular repair for ischemic HFrEF patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.